SCIENTIFIC PLENARY I: INNOVATIVE AND PRACTICE-CHANGING CONCEPTS IN GYNECOLOGIC ONCOLOGY, ABSTRACTS 1-6, Saturday, March 22, 2014, 8:25 a.m. – 9:30 a.m. Ballroom B-C

ABSTRACT 1
Spatial analysis of geographic location and adherence to treatment guidelines for advanced-stage ovarian cancer: impact of race and socioeconomic status

ABSTRACT 2
A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study

ABSTRACT 3
Comparison of the performance of human papillomavirus (HPV) primary screening strategies with cytology-based strategies: results from the ATHENA trial 3-year follow-up phase

Lecturette:
Wendy Brewster, MD, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

ABSTRACT 4
Bariatric surgery decreases the risk of uterine malignancy

ABSTRACT 5
A cost-utility analysis of Gynecologic Oncology Group protocol 218: the importance of incorporating prospectively collected quality-of-life scores in health outcomes research

Lecturette: The TCGA Concept
Kathleen Moore, MD

ABSTRACT 6
Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: contextualizing findings from The Cancer Genome Atlas Research Network

Questions and Floor Discussion
ABSTRACT 7
Long noncoding RNA HOTAIR is associated with human cervical cancer progression

ABSTRACT 8
Biological effects of metformin in a preoperative window clinical trial for endometrial cancer

ABSTRACT 9
Omentin: a potential tumor suppressor in the microenvironment associated with visceral obesity

ABSTRACT 10
Germline mutations in DNA repair genes in women with ovarian, peritoneal, or Fallopian tube cancer treated on GOG protocols 218 and 262

ABSTRACT 11
Molecular profiling of tumors from stage I versus stage III/IV cancer patients: a prediction signature for metastasis in Gynecologic Oncology Group 8024

Lecturette:
Jeff Boyd, MD, Fox Chase Cancer Center, Philadelphia, PA

Questions and Floor Discussion

ABSTRACT 12
Operative outcomes among a geriatric population of endometrial cancer patients: an ancillary data analysis of Gynecologic Oncology Group study LAP2

ABSTRACT 13
Comparative effectiveness of radical hysterectomy in elderly women with cervical cancer

ABSTRACT 14
Sexual function among older female cancer survivors

Lecturette:
Don Dizon, MD, FACP, Massachusetts General Hospital/Harvard University, Boston, MA

ABSTRACT 15
Baseline characteristics and concerns of cancer patients/survivors seeking treatment at a female sexual medicine program

ABSTRACT 16
Evaluation of a multifaceted vaginal health program in gynecologic cancer patients experiencing sexual dysfunction: a randomized controlled trial

Lecturette: Stacy Lindau, MD, University of Chicago, Chicago, IL
FOCUSED PLENARY III: SURGICAL FILM SESSION, ABSTRACTS 17-22, Saturday, March 22, 2014, 11:00 a.m. - 12:10 p.m. Ballroom B-C

ABSTRACT 17
Development and robotic dissection of a novel pelvic lymphadenectomy model

ABSTRACT 18
Resection of a gastrospenic ligament tumor in a patient with recurrent stage IA uterine papillary serous carcinoma

ABSTRACT 19
Robotic-assisted total intracorporeal ileal loop urinary diversion

ABSTRACT 20
High-resolution anoscopy for the detection of anal intraepithelial neoplasia

ABSTRACT 21
Resection of aortocaval lymphadenopathy in a patient with metastatic serous carcinoma of the Fallopian tube

ABSTRACT 22
Recurrent vulvar carcinoma treated with robotic infralevator total pelvic exenteration: a minimally invasive alternative for the elderly population

Questions and Floor Discussion

FEATURED POSTER SESSION I: INTERNATIONAL EFFORTS TO END GYNECOLOGIC CANCERS, ABSTRACTS 23-36, Saturday, March 22, 2014, 2:00 p.m. – 3:00 p.m. Rooms 13-16

ABSTRACT 23
External validation of an all-stage ovarian cancer nomogram: is BRCA status more predictive than family history?

ABSTRACT 24
Increased incidence and poor prognosis of breast cancer in postmenopausal women with high body mass index attending a mammography screening program in the province of Modena (Italy)

ABSTRACT 25
Nutritional Risk Index as a significant prognostic factor in advanced-stage epithelial ovarian cancer patients

Discussant: Ram Eitan, MD

ABSTRACT 26
Nonradical surgery for small early-stage cervical cancer: is it time?

ABSTRACT 27
Radical trachelectomy in early-stage cervical cancer: is minimally invasive surgery the new standard of care?

ABSTRACT 28
A phase III randomized clinical trial of laparoscopic (TLRH) or robotic radical hysterectomy (RRH) versus abdominal radical hysterectomy (ARH) in patients with early-stage cervical cancer: preliminary quality-of-life outcomes
ABSTRACT 29
Long-term outcomes and survival prognostic factors in patients with positive nodes treated by neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer

ABSTRACT 30
Prognostic value of pretreatment total-lesion glycolysis calculated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with locally advanced cervical cancer

ABSTRACT 31
Comparing intensity-modulated radiotherapy and conventional external beam radiotherapy in cervical cancer

Discussant: Carlos Andrade, MD, Barretos Cancer Hospital, Barretos, Brazil

ABSTRACT 32
Factors associated with recommending human papillomavirus (HPV) vaccines among nurses working in a tertiary hospital in South Africa

ABSTRACT 33
Triage of women with negative cytology and positive high-risk human papillomavirus (HPV) DNA testing: an analysis of data from the SHENCCAST (Shenzhen Cervical Cancer Screening Program) II/III studies

ABSTRACT 34
Endometrial cancer: preoperative and intraoperative assessment of myometrial invasion - comparison between MRI and intraoperative examination

ABSTRACT 35
Cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer

ABSTRACT 36
The impact of body mass index on radiotherapy technique in patients with early-stage endometrial cancer: a single-center dosimetric study

Discussant: Linus Chuang, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Questions and Floor Discussion

SCIENTIFIC PLENARY II: HUGH R.K. BARBER LECTURESHIP: GLOBAL EFFORTS TO END CERVICAL CANCER, ABSTRACTS 37-40, Saturday, March 22, 2014, 4:00 p.m. – 5:45 p.m. Ballroom B-C

ABSTRACT 37
Development and validation of a new HPV genotyping assay based on next generation sequencing

Lecturette:
Elise Kohn, MD, National Cancer Institute, Rockville, MD

ABSTRACT 38
The community prevalence of human papillomavirus (HPV) in India and the feasibility of self-collected vaginal swabs

ABSTRACT 39
Difficulty with single-visit approach (SVA) for colposcopy and cervical intraepithelial neoplasia (CIN) treatment in Goma/RDC
ABSTRACT 40
Mexican Cervical Cancer Screening Study II (MECCS II): 6-month and 2-year follow-up

Lecturette:
Kathleen Schmeler, MD, MD Anderson Cancer Center, Houston, Texas

Questions and Floor Discussion

FEATURED POSTER SESSION II: PREDICTORS OF OUTCOMES IN OVARIAN CANCER/TRANSLATIONAL SCIENCE, ABSTRACTS 41-54, Sunday, March 23, 2014, 6:30 a.m. – 7:30 a.m., Rooms 13-16

ABSTRACT 41
The impact and interaction of preoperative disease burden, complex surgery, and residual disease in patients with advanced stage ovarian cancer and the effect on patient survival: A GOG 182 analysis

ABSTRACT 42
BRCA1/2 protein expression as a potential marker of the BRCAaness syndrome in ovarian cancer

ABSTRACT 43
Identification of candidate circulating cisplatin resistance biomarkers from epithelial ovarian carcinoma cell secretomes

ABSTRACT 44
MicroRNA 206 is associated with longer overall survival and platinum sensitivity in serous epithelial ovarian cancer

ABSTRACT 45
The significance of prior tubal occlusion in uterine papillary serous carcinoma

ABSTRACT 46
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced-stage serous ovarian or primary peritoneal cancer: a Gynecologic Oncology Group (GOG) study

Discussant: Victoria Bae-Jump, MD, PhD, University of North Carolina School of Medicine, Chapel Hill, NC

ABSTRACT 47
Developing novel aldehyde dehydrogenase inhibitors to target ovarian cancer stem cells

ABSTRACT 48
Wound healing gone awry: role for platelets in tumor growth after antiangiogenic therapy

ABSTRACT 49
Pathogenesis of ARID1A-driven gynecologic cancer

ABSTRACT 50
Natural killer cells derived from human-induced pluripotent stem cells: an “off the shelf” strategy for killing ovarian cancer

Discussant: Dineo Khabele, MD, Vanderbilt University, Nashville, TN

ABSTRACT 51
More is not always better: thrombocytosis contributes to impaired chemotherapy response in ovarian cancer
ABSTRACT 52
Pharmacologic inhibition of the DNA damage response kinases ATR (ataxia telangiectasia and rad3 related) and ATM (ataxia telangiectasia mutated) broadly sensitizes diverse subtypes of gynecologic cancer cells to ionizing radiation

ABSTRACT 53
Inhibition of gamma-secretase activity in combination with carboplatin and paclitaxel precludes uterine papillary serous carcinoma growth in a primary human xenograft model

ABSTRACT 54
Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells

Discussant: John Liao, MD, University of Washington, Seattle, WA

Questions and Floor Discussion

SCIENTIFIC PLENARY III: THE FARR NEZHAT SURGICAL INNOVATION SESSION, ABSTRACTS 55-58, Sunday, March 23, 2014, 7:45 a.m. – 9:20 a.m. Ballroom B-C

ABSTRACT 55
The sensitivity of sentinel lymph nodes identified with robotic fluorescence imaging for detecting metastatic endometrial cancer: interim results from the FIRES trial

ABSTRACT 56
Sentinel lymph node mapping for uterine cancer: a practical illustration of injection and mapping techniques

ABSTRACT 57
Isolated sentinel lymph node biopsy with conservative management in women diagnosed with vulvar cancer

ABSTRACT 58
Abdominal radical trachelectomy (ART): what’s the role in fertility-sparing surgery for cervical malignancies?

SCIENTIFIC PLENARY IV: PREDICTORS OF OUTCOMES IN GYNECOLOGIC CANCERS: WHAT CAN WE LEARN, ABSTRACTS 59-64, Sunday, March 23, 2014, 11:00 a.m. – 12:45 p.m. Ballroom B-C

ABSTRACT 59
A prospective trial evaluating the ability of preoperative CT scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, Fallopian tube, and peritoneal cancer

ABSTRACT 60
Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis

ABSTRACT 61
Molecular predictors of residual disease in patients with ovarian cancer

Lecturette:
Beth Karlan, MD, Cedars-Sinai Medical Center, Los Angeles, CA
ABSTRACT 62
Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, Fallopian tube, and peritoneal cancers: A GOG study

ABSTRACT 63
Frailty index predicts severe complications in gynecologic oncology patients

ABSTRACT 64
Preoperative quality of life in gynecologic oncology patients: a new predictor of operative risk?

Lecturette:
Vivian von Gruenigen, MD, Northeast Ohio Medical University, Rootstown, OH

Questions and Floor Discussion

FEATURED POSTER III: OVARIAN CANCER: INNOVATIONS AND CONTROVERSIES, ABSTRACTS 65-69, Sunday, March 23, 2014, 12:45 p.m. – 1:30 p.m. West Hall

ABSTRACT 65
An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs. serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group (GOG) experience

ABSTRACT 66
Comparative effectiveness of treatments for recurrent ovarian cancer

Discussant: Anil Sood, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

ABSTRACT 67
Short-term morbidity and mortality associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent/advanced-stage ovarian cancer

ABSTRACT 68
Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese patients with ovarian/Fallopian tube/primary peritoneal carcinoma?

ABSTRACT 69
Launching personalized surgical therapy for advanced ovarian cancer

Discussant: Laurel Rice, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI

FOCUSED PLENARY IV: INNOVATIONS IN IMMUNOTHERAPY, ABSTRACTS 70-74, Sunday, March 23, 2014, 1:45 p.m. – 3:00 p.m. Ballroom D

ABSTRACT 70
Phase I evaluation of therapeutic HPV16 E7 vaccination before resection of HPV16+ CIN2/3

ABSTRACT 71
Phase II trial of paclitaxel, 13-cis retinoic acid, and interferon-alfa-2b in the treatment of advanced stage or recurrent cervical cancer
Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention and monitoring impact of current and future (9-valent) HPV vaccines in the United States

Lecturette:
Warner Huh, MD, University of Alabama at Birmingham, Birmingham, AL

Combination immunotherapy enhances survival in patients with recurrent ovarian cancer

A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: preliminary safety and immunogenicity

Lecturette:
Monica Brown Jones, MD, MS, FACS, FACOG, Cancer Centers of North Carolina, Raleigh, NC

Questions and Floor Discussion

FOCUSED PLENARY V: OBESITY INDUCED CHALLENGES IN ENDOMETRIAL CANCER, ABSTRACTS 75 – 79, Sunday, March 23, 2014, 1:45 p.m. – 3:00 p.m. Ballroom A

The economic impact associated with caring for the morbidly obese with endometrial cancer: a nationwide study of 6,560 women

Complications and surgical staging of endometrial cancer with respect to obesity: a Gynecologic Oncology Group LAP2 ancillary data study

Lecturette: Tips and Tricks for Operating on the Super Morbidly Obese
Pamela Stone, MD, University of Arkansas, Little Rock, AR

The link between obesity and endometrial cancer: a lack of knowledge but an opportunity for intervention

Novel exercise, weight loss, and dietary approach to your life study (NEWDAY) in overweight endometrial and breast cancer survivors

Metformin and the risk of endometrial cancer: a population-based cohort study

Lecturette: Overview of obesity in endometrial cancer and future directions
Angeles Secord, MD, Duke University Medical Center, Durham, NC

Questions and Floor Discussion
FEATURED POSTER SESSION IV: CANCER IN ELDERLY AND UNDERSERVED POPULATIONS,
ABSTRACTS 80 – 93, Monday, March 24, 2014, 7:00 a.m. – 8:00 a.m. Ballroom A

ABSTRACT 80
Dose delay, but not dose reduction, in chemotherapy administration is associated with decreased survival in elderly women with ovarian cancer

ABSTRACT 81
An American College of Surgeons-National Surgical Quality Improvement Project (ACS-NSQIP) evaluation of surgical outcomes in the elderly: endometrial cancer patients undergoing hysterectomy

ABSTRACT 82
Gaps in adjuvant treatment in elderly endometrial cancer patients

ABSTRACT 83
Improving quality of care with cervical cancer patient navigation

ABSTRACT 84
Risk factors and impact of refusing recommended therapy in cervical cancer: a National Cancer Data Base (NCDB) study

Discussant: Trey Leath, MD, University of Alabama at Birmingham, Birmingham, AL

ABSTRACT 85
Preoperative chlorhexidine wipes reduce the risk of surgical-site infections after hysterectomy

ABSTRACT 86
The risk factors for readmission in postoperative gynecologic oncology patients at a single institution

ABSTRACT 87
Surgeons as active leaders in the operating room: potential cost-saving behaviors

ABSTRACT 88
Gynecologic surgical-site infection reduction program (GSRP): a successful quality improvement project in reducing the incidence of surgical-site infection

ABSTRACT 89
Characteristics of high-volume gynecologic cancer centers – framework toward centers of excellence: a National Cancer Data Base (NCDB) study

Discussant: Kian Behbakht, MD, University of Colorado, Denver, CO

ABSTRACT 90
The role of adjuvant radiation and chemoradiation in single node-positive vulvar cancer

ABSTRACT 91
Barriers to human papillomavirus (HPV) vaccination: perspectives of parents of vaccine-eligible children

ABSTRACT 92
Human papillomavirus vaccination within a Southern California integrated healthcare system demonstrates disparities in adherence rates among males and females compared to national reports

ABSTRACT 93
Magnitude of increased lifetime risk of cervical cancer and death from cervical cancer with new screening recommendations

Discussant: Diljeet Singh, MD, Banner MD Anderson Cancer Center, Gilbert, AZ
Questions and Floor Discussion

**FEATURED POSTER SESSION V: CLINICAL TRIALS AND DRUG REPURPOSING, ABSTRACTS 94 – 105, Monday, March 24, 2014, 7:00 a.m. – 8:00 a.m. Rooms 13-16**

**ABSTRACT 94**
Impact of age on tolerance of chemoradiation and survival for patients with local regionally advanced cervical cancer: a pooled analysis of Gynecologic Oncology Group (GOG) phase III trials

**ABSTRACT 95**
Do elderly women with endometrial cancer qualify for existing clinical trials?

**ABSTRACT 96**
Patient and physician factors associated with participation in Gynecologic Oncology Group (GOG) trials in cervical and uterine cancer

**Discussant:** Joan Walker, MD, *The University of Oklahoma, Oklahoma City, OK*

**ABSTRACT 97**
A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study

**ABSTRACT 98**
Phase I trial results of a folate receptor alpha-directed cancer vaccine (E39) in ovarian and endometrial cancer patients to prevent recurrence

**ABSTRACT 99**
Effect of *BRCA1* and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study

**ABSTRACT 100**
Phase II trial of pemetrexed and carboplatin in platinum-sensitive recurrent ovarian, Fallopian tube, and primary peritoneal cancer

**ABSTRACT 101**
Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

**Discussant:** Carolyn Muller, MD, *University of New Mexico, Albuquerque, NM*

**ABSTRACT 102**
Not your mother’s bisphosphonate: targeting angiogenesis in ovarian cancer

**ABSTRACT 103**
Aspirin and acetaminophen decrease the risk of cervical cancer in long-term users

**ABSTRACT 104**
Endometrial cancer outcomes in diabetic women treated with metformin, statins, and aspirin

**ABSTRACT 105**
Metformin has increased efficacy under obese conditions in a novel genetically engineered mouse model of serous ovarian cancer
Discussant: Carolyn Muller, MD, University of New Mexico, Albuquerque, Albuquerque, NM

Questions and Floor Discussion

SCIENTIFIC PLENARY V: LATE-BREAKING ABSTRACTS, ABSTRACT 106, Monday, March 24, 2014, 8:15 a.m. – 9:50 a.m. Ballroom B-C

ABSTRACT 106
Burnout is associated with decreased career satisfaction and psychosocial distress among members of the Society of Gynecologic Oncology

SCIENTIFIC PLENARY SESSION VI: APPROACHES TO IMPROVE QUALITY AND PALLIATIVE CARE IN GYNECOLOGIC CANCERS, ABSTRACTS 107 – 110, Monday, March 24, 2014, 2:30 p.m. – 3:30 p.m. Ballroom B-C

ABSTRACT 107
Hospital readmission (30-day) following surgery for advanced-stage ovarian cancer: analysis of risk factors and cost using the SEER-Medicare database

ABSTRACT 108
Cost analysis comparing universal tumor testing to clinically based criteria in the evaluation of endometrial adenocarcinomas for Lynch syndrome

Lecturette:
Randall Gibb, MD, Billings Clinic, Billings, MT

ABSTRACT 109
Outpatient palliative care consultation is associated with a decrease in symptom burden for women with gynecologic malignancies

ABSTRACT 110
Predictors of palliative care consultation on an inpatient gynecologic oncology service: are we following ASCO recommendations?

Lecturette:
Lois Ramondetta, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Questions and Floor Discussion

FEATURED POSTER SESSION VI: HEREDITARY/MINIMALLY INVASIVE SURGERY/OBESITY/SURVIVORSHIP AND PALLIATIVE CARE, ABSTRACTS 111-130, Monday, March 24, 2014, 3:35 p.m. – 4:45 p.m. Ballroom D

HEREDITARY

ABSTRACT 111
Interim analysis of a prospective pilot study of risk-reducing postpartum distal salpingectomy

ABSTRACT 112
Risk management options elected by women after testing positive for a BRCA1 or BRCA2 variant of unknown significance mutation
ABSTRACT 113
Women with dual gynecologic primary cancers can have mutations in Lynch syndrome genes or BRCA1/BRCA2, reflecting the overlap in clinical histories between these syndromes

ABSTRACT 114
Preoperative genetic testing affects surgical decision-making in breast cancer patients

Discussant: Noah Kauff, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

MINIMALLY INVASIVE SURGERY

ABSTRACT 115
Racial disparity in endometrial cancer patients undergoing hysterectomy: an American Cancer Society (ACS)-National Surgical Quality Improvement Program (NSQIP) evaluation of surgical outcomes

ABSTRACT 116
Disparities in the use of robotic surgery in endometrial cancer based on race and socioeconomic status in the United States

ABSTRACT 117
The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications

ABSTRACT 118
Patterns of recurrence and survival after randomization to laparoscopy versus laparotomy in women with high-grade uterine cancer: a Gynecologic Oncology Group (GOG) study

ABSTRACT 119
Is robotic-assisted surgery safe in the elderly population? An analysis of gynecologic procedures in patients ≥65 years old

Discussant: Paola Gehrig, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

OBESITY

ABSTRACT 120
The influence of obesity on disease characteristics and survival among patients with epithelial ovarian cancer

ABSTRACT 121
Differential gene expression was associated with increasing body mass index (BMI) among endometrial cancers from The Cancer Genome Atlas (TCGA) Project

ABSTRACT 122
The use of technology-based weight loss intervention for endometrial cancer survivors with obesity

ABSTRACT 123
Maximizing minimally invasive surgical approaches in the morbidly obese patient with newly diagnosed uterine cancer

ABSTRACT 124
Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity for improving patient-centered outcomes

Discussant: Amir Jazaeri, MD, University of Virginia, Charlottesville, VA
ABSTRACT 125
Cervical cancer treatment and survivorship needs: the patient’s perspective

SURVIVORSHIP/PALLIATIVE CARE

ABSTRACT 126
A prospective study of the preferences of women with ovarian cancer

ABSTRACT 127
Predicting 6- and 12-month risk of mortality in patients with platinum-resistant advanced-stage ovarian cancer: toward development of a nomogram to guide palliative referrals

ABSTRACT 128
Clinical triggers for inpatient palliative care consultation in gynecologic oncology: a needs assessment

ABSTRACT 129
Assessment of palliative care training in gynecologic oncology: a Gynecologic Oncology Fellows Research Network study

ABSTRACT 130
Too much, too late: aggressive measures and the timing of end-of life care discussions in women with gynecologic malignancies

Discussant: Ellen Smith, MD, Texas Oncology, Austin, TX

Questions and Floor Discussion

FOCUSED PLENARY SESSION VI: CLINICAL TRIALS IN GYNECOLOGIC ONCOLOGY: A FOCUS ON TARGETED THERAPIES, ABSTRACTS 131 – 135, Monday, March 24, 2014, 3:35 p.m. - 4:45 p.m. Ballroom B-C

ABSTRACT 131
A phase I study of veliparib (ABT-888) in combination with carboplatin and gemcitabine in subjects with advanced ovarian cancer

ABSTRACT 132
Analysis of intermediate clinical endpoints from a phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

Lecturette:
Elizabeth Swisher, MD, University of Washington Medical Center, Seattle, WA

ABSTRACT 133
Results of Gynecologic Oncology Group (GOG) 229K: a phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma

ABSTRACT 134
Outpatient treatment of malignant ascites in patients with advanced gynecologic carcinomas: a single-institution experience with intraperitoneal application of the trifunctional monoclonal antibody catumaxomab

ABSTRACT 135
R-ketorolac as a GTPase inhibitor: phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients
Lecturette:
Michael Bookman, MD, The Arizona Cancer Center, Tucson, AZ

Questions and Floor Discussion

SCIENTIFIC PLENARY VII: OVARIAN CANCER CLINICAL TRIALS: ENDPOINT VALIDATION AND PRACTICE-CHANGING RESULTS, ABSTRACTS 136 – 139, Tuesday, March 25, 2014, 7:30 a.m. – 9:00 a.m. Ballroom B-C

ABSTRACT 136
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

ABSTRACT 137
Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

ABSTRACT 138
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

ABSTRACT 139
Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262

SEMINAL ABSTRACT: 1
Presentation of seminal clinical data from Gynecologic Oncology Group study 262
(Presented at the European Society of Gynecologic Oncology)

Questions and Panel Discussion

SCIENTIFIC PLENARY VIII: SEMINAL ABSTRACT SESSION: ROLE OF ANTI-ANGIOGENIC AGENTS IN OVARIAN CANCER, SEMINAL ABSTRACTS 2 – 4, 9:00 a.m. - 10:10 a.m. Ballroom B-C

SEMINAL ABSTRACT: 2
ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer

SEMINAL ABSTRACT: 3
ICON 6: Randomized Double-Blind Phase III trial of Cediranib (AZD 2171) in relapsed platinum-sensitive ovarian cancer: Results of the ICON 6 Trial

SEMINAL ABSTRACT: 4
A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1

Lecturette: Overview of current anti-angiogenesis Robert Coleman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
SCIENTIFIC PLENARY IX: MULTIMODAL THERAPY AND PREDICTORS OF RESPONSE, ABSTRACTS 140 – 145, Tuesday, March 25, 2014, 10:25 a.m. - 11:50 a.m. Ballroom B-C

ABSTRACT 140
Concurrent chemoradiation with paclitaxel in high-risk endometrial cancer patients after surgery: a Korean Gynecologic Oncology Group study

ABSTRACT 141
Multimodal therapy improves progression-free survival in patients with stage I-III uterine carcinosarcoma: a multi-institutional study

ABSTRACT 142
A cost-effectiveness analysis of four chemotherapy regimens used in the treatment of platinum-sensitive recurrent epithelial ovarian carcinoma

ABSTRACT 143
Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study

ABSTRACT 144
High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: a Gynecologic Oncology Group (GOG) study

ABSTRACT 145
A comparative analysis of the treatment strategies for advanced ovarian cancer

Questions and Floor Discussion

POSTER SESSION A, Saturday, March 22, 2014, Exhibit Hall

Breast Cancer, Cervical Cancer, Chemotherapy, Clinical Practice Issues, Hereditary Cancers and the Role of Genetics, Ovarian/Fallopian Tube/Primary Peritoneal Cancer, Translational Research/Basic Science and Uterine/Endometrial Cancer

BREAST CANCER
Poster 146: The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome

CERVICAL CANCER
Poster 147: Analysis of the effect of adjuvant radiotherapy on outcome and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors

Poster 148: The impact of multiple high-risk factors on survival outcome of surgically treated early-stage cervical cancer

Poster 149: Cervical adenocarcinoma in situ with coexisting squamous cell lesions: impact on recurrence

Poster 150: A new suggested pattern-based clinical classification system for endocervical adenocarcinoma

Poster 151: Differentiation between high- and low-grade cervical intraepithelial neoplasia by p16 immunoeexpression

Poster 152: Risk factors for cervical intraepithelial neoplasia (CIN) recurrence in patients with positive cone margins
**Poster 153:** The diagnostic utility of HR-HPV as a predictor of cervical cancer recurrence

**Poster 154:** Synaptonemal complex protein 3 is a prognostic marker in cervical cancer

**Poster 155:** MICA/B and ULBP1 natural killer group 2 member D (NKG2D) ligands are independent predictors of prognosis in cervical cancer

**Poster 156:** Impact of treatment time on chemoradiotherapy in locally advanced cervical carcinoma

**Poster 157:** Makorin ring finger protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology

**Poster 158:** High rates of cervical intraepithelial neoplasia (CIN) 3 in young women undergoing immediate excisional procedure for high-grade squamous intraepithelial lesion (HSIL) cytology

**Poster 159:** Fertility-sparing surgery after high dose-dense neoadjuvant chemotherapy: critical view of experiences with 25 patients

**Poster 160:** Efficacy of adjuvant chemotherapy after radical hysterectomy in FIGO stage IB-IIA cervical cancer: comparison with adjuvant RT/CCRT using Propensity Scores

**Poster 161:** Less radical surgery than radical trachelectomy or radical hysterectomy in patients with stage I cervical cancer

**Poster 162:** A study of safe criteria for radical trachelectomy in cervical cancer patients to prevent recurrence and catastrophic consequences: a multicenter study

**Poster 163:** Less radical surgery for early-stage cervical cancer: can cold knife cone specimens help identify those at low risk for parametrial involvement?

**Poster 164:** Adenocarcinoma indicates more favorable prognosis with cervix cancer

**Poster 165:** Diagnosis of adenocarcinoma in situ (AIS): changing trends and the impact of human papillomavirus (HPV) testing

**Poster 166:** Prognostic role of maximum standardized uptake value of metastatic pelvic lymph node in patients with early-stage cervical cancer for the prediction of distant metastasis

**CHEMOTHERAPY**

**Poster 167:** Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience

**Poster 168:** A dose-dense paclitaxel and carboplatin regimen is highly active in the treatment of recurrent and advanced endometrial cancer

**Poster 169:** Oxaliplatin is a safe alternative therapeutic option for patients with recurrent gynecologic cancers following hypersensitivity reaction to carboplatin

**Poster 170:** Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery

**Poster 171:** A dose a day keeps the cancer away: metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer

**Poster 172:** Nanoparticle albumin-bound (nab) paclitaxel therapy in patients with primary and recurrent ovarian, Fallopian tube, and primary peritoneal carcinoma

**Poster 173:** Serum antibodies recognizing hypoxia-inducible factor 1-alpha and platinum sensitivity in ovarian cancer
**Poster 174:** Is it equivalent? a comparison of the clinical activity of Lipodox compared to Doxil in the treatment of recurrent ovarian cancer

**CLINICAL PRACTICE ISSUES**

**Poster 175:** Semi-quantitative human papillomavirus virus (HPV) viral load correlates with the presence and grade of preneoplastic lesions of the uterine cervix in patients with atypical squamous cells of undetermined significance (ASCUS) cytology

**Poster 176:** Narrative medicine: using reflective writing workshops to help house staff address the complex and challenging nature of caring for gynecologic oncology patients

**Poster 177:** Evaluating an adnexal mass using a multivariate index assay and imaging

**Poster 178:** Is hysterectomy safe after concurrent radiochemotherapy of cervical cancer?

**Poster 179:** Determinants of pelvic and para-aortic lymph node metastasis in endometrial cancer and its role in tailoring lymphadenectomy

**Poster 180:** Perioperative thromboembolism prophylaxis: how much is enough?

**Poster 181:** Malignant endometrial polyps in uterine serous carcinoma: does size matter?

**Poster 182:** Trends in patient care after discontinuation of daily progress checklists after transition to electronic patient documentation: evaluation of prophylactic compliance and surgical outcomes among gynecologic oncology patients

**Poster 183:** Preoperative hypoalbuminemia is a risk factor for 30-day morbidity after gynecologic malignancy surgery

**Poster 184:** Factors associated with clinical trial screening failures in gynecologic oncology

**Poster 185:** Prediction model for 30-day morbidity after gynecologic malignancy surgery

**Poster 186:** Gynecologic oncology fellow perspectives on research and career development symposia: a Gynecologic Oncology Fellows’ and Allied Health Professionals’ Research Network (GOFRN) survey study

**HEREDITARY CANCERS AND THE ROLE OF GENETICS**

**Poster 187:** Assessment of primary care providers’ current clinical practices in determining a woman’s risk for ovarian cancer

**Poster 188:** A new Lynch syndrome: what is the role for polymerase D1 mutations in hereditary endometrial cancer?

**Poster 189:** Prevalence and clinical predictors of germline PTEN mutation in endometrial cancer patients with Cowden and Cowden-like syndrome

**Poster 190:** Germline SDHB/C/D variation and KLLN promoter methylation in endometrial cancer patients with Cowden and Cowden-like syndrome

**Poster 191:** PD-0332991, a cyclin-dependent kinase 4/6 inhibitor, is an active agent in uterine cancer cells

**Poster 192:** Exome sequencing identifies germline mutations involving novel single nucleotide polymorphisms within DNA repair pathway genes in uterine serous carcinoma

**Poster 193:** Breast cancer risk with hormone replacement after risk-reducing salpingo-oophorectomy in BRCA mutation carriers: does it abrogate the benefit?
**Poster 194:** A KRAS hot spot mutation correlates with MLH1 methylation in endometrial carcinomas with microsatellite instability: a potential triage tool for Lynch syndrome evaluation

**Poster 195:** Genetic mutations and characteristics of “resistant” BRCA1 and BRCA2 carriers cohort

**Poster 196:** Gene expression profiles of high-grade serous ovarian cancers in patients with normal CA-125 levels at the time of recurrence

**Poster 197:** Association of in vitro chemotherapy drug resistance assays in ovarian cancer patients with BRCA1/2 mutations

**OVARIAN/FALLOPIAN TUBE/PRIMARY PERITONEAL CANCER**

**Poster 198:** Inhibition of chaperone-mediated autophagy may be a novel approach to increase platinum susceptibility in ovarian cancer cell lines

**Poster 199:** The management of peritoneal surface malignancies: single-center initial experience

**Poster 200:** The mTOR inhibitor RAD001 exhibited more efficacy against ovarian cancer ascites after pharmacologic inhibition of Mirk kinase

**Poster 201:** The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass

**Poster 202:** Do high-grade stage I ovarian cancers benefit from adjuvant chemotherapy?

**Poster 203:** Risk factors for progression to invasive carcinoma in patients with borderline ovarian tumors

**Poster 204:** Clinicopathological prognostic factors for recurrence in adult granulosa cell tumor of the ovary

**Poster 205:** Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer

**Poster 206:** Clinical response to anti-estrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status

**Poster 207:** Impact of lymphovascular space invasion (LVSI) on survival of stage I epithelial ovarian cancer

**Poster 208:** Preoperative predictors which impact the survival and outcome of secondary cytoreduction in ovarian cancer

**Poster 209:** Tumor microvessel density does not correlate with bevacizumab response in recurrent ovarian cancer

**Poster 210:** Outcome and response to neoadjuvant chemotherapy in patients with advanced stage Müllerian cancer in BRCA1/2 mutation-positive compared to mutation-negative women

**Poster 211:** MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy

**Poster 212:** HNF1B contributes to resistance to oxidative stress through modification of metabolism in ovarian clear cell carcinoma

**Poster 213:** Utility of serum folate-binding protein as a biomarker in the monitoring and treatment of ovarian cancer

**Poster 214:** BCL2 antagonist of cell death (BAD) gene sequence and functional analysis of phosphorylation sites in ovarian cancer
**Poster 215**: Incidence of lymph node metastasis in comprehensively staged clear cell carcinoma grossly confined to the ovary

**Poster 216**: The role of secondary cytoreduction in patients with recurrent low-grade serous ovarian carcinoma

**Poster 217**: Significance of serum CA-125 level as a prognostic factor after the first cycle of chemotherapy in patients with advanced serous epithelial ovarian cancer

**Poster 218**: The Charlson Comorbidity Index predicts survival in women with epithelial ovarian cancer independent of surgical debulking status

**Poster 219**: Targeting PI3K/AKT signaling and the TR3/NR4A1 receptor in ovarian cancer

**Poster 220**: Forkhead box M1 (FOXM1) gene expression inversely correlates with survival and targeting FOXM1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian cancer ascites cells ex vivo

**Poster 221**: A mycobacterial heat shock protein 70-based fusion protein targeting mesothelin induces dendritic cell maturation and cross-presentation in a murine model of ovarian carcinoma

**Poster 222**: Pelvic magnetic resonance imaging diagnosis correlates with pathology of adnexal masses

**Poster 223**: The presence of endometriosis is associated with improved survival in epithelial ovarian cancer

**Poster 224**: Characterization of primary platinum resistance in an era of biologic agents and novel chemotherapeutic design

**Poster 225**: Primary debulking surgery in stage IIIC and IV ovarian cancer results in improved survival compared to those undergoing neoadjuvant chemotherapy with interval cytoreduction

**Poster 226**: Hypomethylation signature enriches stem properties and predicts poor prognosis for ovarian cancer patients

**Poster 227**: Hyperthermic intraperitoneal chemotherapy in the treatment of ovarian, Fallopian tube, and peritoneal cancer: an analysis of recurrence patterns and survival

**Poster 228**: A "REST-less" phenotype is associated with favorable recurrence-free survival in ovarian cancer

**Poster 229**: Subcellular localization of AT-rich interactive domain1A protein expression is associated with survival in epithelial ovarian and peritoneal carcinoma

**Poster 230**: An analysis of short-term morbidity associated with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer

**Poster 231**: Correlation of positron emission tomography (PET) with CA-125 levels in predicting recurrence in ovarian cancer

**Poster 232**: Identification of differentially expressed miRNAs in ovarian cancer from endometriosis in the same patient

**Poster 233**: Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors

**Poster 234**: Reliability and reproducibility of 99mTc-etarfolatide for identification of patient folate receptor status
Poster 235: HGF/c-Met axis drives cancer aggressiveness in the neoadjuvant setting of ovarian cancer
Poster 236: Hitting the right mark: nonoverlapping Notch and PI3K alterations in ovarian cancer
Poster 237: Clinicopathologic benchmark for prognostic modeling of advanced epithelial ovarian cancer long-term survival: a Gynecologic Oncology Group (GOG) analysis
Poster 238: Serum antibodies recognizing BRCA1 at time of diagnosis and primary platinum resistance in ovarian cancer
Poster 239: Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer
Poster 240: Venous thromboembolism carries particularly grave prognosis with epithelial ovarian cancer
Poster 241: Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
Poster 242: Inhibition of HIF1α promotes paclitaxel efficacy in CD133+ ovarian carcinoma cells
Poster 243: The utilization of PET scans in ovarian, Fallopian tube and primary peritoneal carcinoma patients may be associated with improved overall survival
Poster 244: Prognostic factors for overall survival in recurrent ovarian, Fallopian tube, and peritoneal cancer patients treated with bevacizumab: a multi-site study
Poster 245: Prognostic factors in malignant ovarian germ cell tumors
Poster 246: A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer
Poster 247: Nomogram predicting 5-year progression-free survival after secondary surgical cytoreduction for platinum-sensitive recurrent ovarian cancer
Poster 248: Lymphadenectomy in stage I ovarian granulosa cell tumors improves overall survival
Poster 249: Risk of second primary breast cancer among women with epithelial ovarian cancer compared to Fallopian tube cancer
Poster 250: Predicting overall survival after secondary surgical cytoreduction for platinum-sensitive recurrent ovarian cancer: a prognostic nomogram
Poster 251: Acquired platinum resistance among women with high-grade serous epithelial ovarian cancer
Poster 252: Differential expression of Rad51 and NAC1 proteins in primary, metastatic and recurrent high grade serous ovarian cancer
Poster 253: Radiation therapy for recurrent clear cell ovarian carcinoma
Poster 254: An analysis of the survival outcomes of video-assisted thoracic surgery in the primary management of patients with advanced ovarian, tubal, and peritoneal cancer
Poster 255: Canine scent-specific detection of serous ovarian cancer
Poster 256: Robotic and open cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of recurrent ovarian carcinoma
Poster 257: Development of flow cytometric predictive biomarker assay for response to PARP inhibitor (PARPi) therapy in high grade serous ovarian cancer (HGSOC)

Poster 258: Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy

Poster 259: Magneto-electric nanoparticles as field-controlled nano-electroporation sites for high specificity

Poster 260: Treatment of epithelial ovarian cancer with HE4-targeted antisense phosphorothioligos (PTO’s)

Poster 261: Intraperitoneal administration of alpha-emitting isotopes

Poster 262: Impact of new oncolytic herpes simplex virus for cervical cancer therapy

Poster 263: BRCA1 mutation determines the impact of Profilin1 in ovarian cancer cell motility

Poster 264: Yes-associated protein (YAP) functions as a proto-oncogene and promotes radiation resistance in endometrial cancer

Poster 265: Somatic mutations in small cell carcinoma of the ovary

Poster 266: Detection of ovarian cancer biomarkers in routine Pap tests by mass spectrometry based proteomic techniques

Poster 267: Inhibition of autophagy by vaginal fluid from women with malignant adnexal masses

Poster 268: Frequent inactivation of the XAF1 tumor suppressor gene in human ovarian cancer by aberrant promoter CpG sites hypermethylation

Poster 269: Enhanced gynecologic cancer cell killing through pharmacologic inhibition of the Ataxia Telangiectasia and Rad3-related Kinase

Poster 270: HE4 interacts with sex hormones in epithelial ovarian cancer

Poster 271: Novel mechanisms of chemo resistance in ovarian cancer: the role of tunneling nanotubes

Poster 272: FBxW7 duality in ovarian cancer: Novel insight into ovarian cancer pathogenesis

Poster 273: Progestin and vitamin D suppress growth of ovarian cancer in vitro and in vivo

Poster 274: The PI3K inhibitor GDC-0941 is synergistic with lapatinib, and mediates endocrine sensitivity in uterine papillary serous carcinoma via AKT

Poster 275: Subcellular localization and function of IGF2 in uterine carcinosarcoma

Poster 276: The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer

Poster 277: Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer

Poster 278: Binary methylation of human papillomavirus (HPV) L1 and death associated protein kinase (DAPK) as biomarkers of progression in cervical carcinogenesis

Poster 279: Targeting myeloid cells in the tumor microenvironment as a strategy to enhance vaccine efficacy in the epithelial ovarian cancer
Poster 280: Cytokine profiling of ascites identifies macrophage inflammatory protein- beta and tumor necrosis factor-alpha as predictors of progression-free survival in patients with epithelial ovarian cancer

Poster 281: Expression of GPER, ERβ, ERα, and PR in gynecologic sarcomas

Poster 282: Ovarian cancers with nuclear special AT-rich sequence binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug resistant, and deadly

Poster 283: Putative events in the development of clear cell ovarian carcinoma from endometriosis: an evaluation using immunohistochemistry and gene expression profiling

Poster 284: Selective activation of Notch3 in high grade serous ovarian cancer

Poster 285: PARP-inhibition synergizes with anti-CTLA-4 immune therapy to promote rejection of peritoneal tumors in mouse models of ovarian cancer

Poster 286: Tumor cells surviving the cytotoxic effect of paclitaxel are sensitized to anti-cancer peptide PNC-27

Poster 287: Testing the accuracy of mutation detection for the prevention of ovarian neoplasia: the TAMPON study

Poster 288: Dual HER2 targeting impedes growth of HER2 gene amplified uterine papillary serous carcinoma xenografts

Poster 289: Use of SRC pathway activation in predicting dasatinib activity in ovarian cancer

Poster 290: Analysis of the immune cell composition in serous ovarian cancer

Poster 291: Patient-derived tumor Xenograft Model (“Avatar mice”) for gynecologic cancer

Poster 292: The microenvironmental effects of endometriosis on vcam-1 and il-10 expression in early stage epithelial ovarian cancer

Poster 293: Serum omentin concentration is a potential biomarker for complex atypical hyperplasia and endometrioid endometrial cancer

Poster 294: mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer

Poster 295: Curated ovarian database derived identification of genes predicting survival in primary serous epithelial ovarian cancer

Poster 296: Cytokine-induced killer cells from ovarian cancer patients expanded ex vivo in the presence of IL-7 improve survival in a xenograft mouse model of ovarian cancer

Poster 297: Wnt pathway inhibition by niclosamide: a therapeutic target for ovarian cancer

Poster 298: PARP therapy for the genetically unstable: a preclinical evaluation of PARP inhibitors in the treatment of MSI-H endometrial tumors

Poster 299: Copy number variation and mutations associated with ovarian cancer chemo-response

Poster 300: Ovarian cancer ascites stem cell population compared to primary tumor

Poster 301: HSP90 inhibition decreases ovarian cancer cell proliferation and potentiates platinum-sensitivity
Poster 302: Expression profiles of LKB1/AMPK in endometrial cancer specimens as a potential biomarker for targeted metabolic drug therapy

Poster 303: Radioimmunotherapy targeting human papillomavirus E7 oncoprotein demonstrates therapeutic potential and limited toxicity

Poster 304: ALDH1A1 maintains ovarian cancer stem-like cells’ properties by regulating KLF4/p21 mediated signaling cascade

Poster 305: A Hedgehog pathway smoothened inhibitor demonstrated synergy with carboplatin in ovarian cancer via a dual process of receptor enrichment plus regulation of DNA damage processing

Poster 306: Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol-resistant ovarian cancer cells

Poster 307: Establishment and combined genomic and proteomic characterization of patient-derived ovarian cancer cell lines

Poster 308: Initial investigation of combined single-photon emission computed tomography (SPECT) and magnetic resonance (MR) imaging of a human ovarian tumor xenograft using 123I-bevacizumab

Poster 309: Identification of microscopic ovarian tumor foci utilizing a novel imaging device in a murine ovarian cancer model; an opportunity to improve optimal cytoreduction

UTERINE/ENDOMETRIAL CANCER
Poster 310: An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers

Poster 311: Incidence of ovarian metastases in uterine leiomyosarcoma and optimal surgery

Poster 312: Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases

Poster 313: Is rad/let/met more than just a catchy name? A preclinical evaluation of everolimus, letrozole, and metformin in recurrent endometrial cancer

Poster 314: Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

Poster 315: Effective endometrial cancer screening method using liquid-based cytology

Poster 316: A comparison of colorimetric versus fluorometric sentinel lymph node mapping in during robotic surgery for endometrial cancer

Poster 317: Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus

Poster 318: Successful identification of high-risk grade 1 endometrial cancer utilizing MRI, CA125 and BMI before surgery: a prospective quality improvement initiative

Poster 319: Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma

Poster 320: Analyzing the learning curve of robotic assisted sentinel lymph node dissection for endometrial cancer

Poster 321: Does ultrastaging improve detection of micrometastasis for early stage endometrial cancer?
**Poster 322:** Predicting model for lymph node metastasis using preoperative tumor grade, transvaginal ultrasound, and serum CA-125 level in patients with endometrial cancer

**Poster 323:** Outcomes in node-positive low grade endometrioid endometrial carcinoma

**Poster 324:** Age-adjusted charlson comorbidity index is a prognostic factor in patients with early-stage uterine carcinoma. A study with 1132 patients

**Poster 325:** Nodal selection during side-specific lymphadenectomy in cases of failed sentinel node mapping

**Poster 326:** Taking it up a notch: implications for outcomes in endometrial cancer

**Poster 327:** Prognostic factors of lymph node involvement in endometrioid endometrial cancer: a SEER analysis

**Poster 328:** Recurrence and survival in patients with uterine papillary serous carcinoma: Do prior breast cancer and tamoxifen exposure influence outcomes?

**Poster 329:** Expression of DNA repair proteins in endometrial cancer predicts disease outcome

**Poster 330:** Lack of genomic predictors of recurrence in uterine carcinoma

**Poster 331:** Genomic characterization of grade 3 endometrial carcinoma

**Poster 332:** Efficacy of adjuvant therapy in women with stage IIIC2 endometrial cancer

**Poster 333:** Variations in practice for the management of high risk histologic subtypes in endometrial cancer. A CHREC (Consortium of High Risk Endometrial Cancer) Canadian project

**Poster 334:** Proteomic profiling of stage I endometrial cancers: a signature of early stage recurrence in GOG 8016

**Poster 335:** Combined modality adjuvant therapy for FIGO stage IIIC endometrial carcinomas

**Poster 336:** Pelvic sentinel lymph node mapping and aortic nodal status in endometrial cancer: Does infra-renal aortic lymph node metastasis really occur in isolation?

**Poster 337:** Proteomics of endometrial carcinogenesis: identification of candidates underlying disease pathogenesis

**Poster 338:** Large tumors in endometrial cancer: A change in perspective

**Poster 339:** Who should treat complex atypical endometrial hyperplasia?

**Poster 340:** Is observation reasonable in older patients with early stage uterine papillary serous carcinoma and clear cell carcinoma?

**Poster 341:** Association between endometrioid endometrial cancer (EC) risk classification and gene expression in The Cancer Genome Atlas (TCGA) dataset

**Poster 342:** Does the order of surgery and radiation therapy matter in the treatment of stage II endometrial cancer?
POSTER SESSION B, Sunday, March 23, 2014, Exhibit Hall

Cancer Care Delivery System and Payment Reform, Cancer in Vulnerable Populations: Obesity, Elderly and the Underserved, Clinical Trials in Gynecologic Cancers: Phase I, II, III and Trials in Progress, Global Efforts to End Women’s Cancers, Gestational Trophoblastic Disease/Vulvar and Vaginal Cancers/Rare Tumors/Sarcomas, Surgical Techniques/Robotics/Minimally Invasive Surgery, Survivorship and Supportive Care

CANCER CARE DELIVERY SYSTEM AND PAYMENT REFORM

Poster 343: Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer

Poster 344: Availability and scope of integrated screening for patients with Lynch syndrome

Poster 345: Socioeconomic status and health insurance as predictors of access to high-volume hospital care for women with early-stage ovarian cancer

Poster 346: Cost comparison among robotic, laparoscopic, and laparoendoscopic single-site surgery in gynecologic oncology

Poster 347: Use of a perioperative anticoagulation protocol in gynecologic oncology patients receiving continuous epidural analgesia

Poster 348: Body mass index (BMI), postoperative complications, and perioperative resource utilization by hysterectomy approach for patients in a national cohort with endometrial cancer or complex atypical hyperplasia

Poster 349: Use of Lean and Six Sigma methodology to improve clinic efficiency in a high-volume tertiary care gynecologic oncology clinic

Poster 350: An economic analysis of cisplatin alone versus cisplatin doublets in the treatment of women with advanced or recurrent cervical cancer

Poster 351: Safety and cost savings of omitting cardiac surveillance during treatment with pegylated liposomal doxorubicin in gynecologic oncology survivors

Poster 352: Cost-effectiveness analysis of treatment modalities for women with high-intermediate risk endometrial carcinoma: should Gynecologic Oncology Group (GOG) 249 have included a chemotherapy-only arm?

Poster 353: A novel clinical trial recruitment strategy for women’s cancers

Poster 354: Out with the old and in with the neoadjuvant: changes and influences in ovarian cancer practice patterns among Society of Gynecologic Oncology (SGO) members

Poster 355: National Comprehensive Cancer Network (NCCN) guidelines for gynecologic malignancies: where’s the beef?

Poster 356: Clinical utility and cost-effectiveness of preoperative CT in endometrial cancer patients

Poster 357: Improving outcomes in patients with suspected ovarian cancer: a quality improvement program

Poster 358: Cost comparison between in hospital death and discharge to hospice among gynecologic cancer patients
Poster 359: Preoperative imaging of uterine malignancy

Poster 360: Fighting cancer together: shared medical appointments - a feasibility survey

Poster 361: Breast cancer following ovarian cancer in BRCA mutation carriers: what is the cost of surveillance?

Poster 362: Robotic versus abdominal radical hysterectomy for early cervical cancer: a single-center experience

Poster 363: Trends in robotic surgery in uterine cancer: a nationwide study of 13,719 patients

Poster 364: Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?

Poster 365: Multiple lines of chemotherapy in recurrent epithelial ovarian cancer, are more lines better? A decision analytic model

Poster 366: Is the survival advantage gained by the addition of bevacizumab to chemotherapy for the treatment of recurrent, persistent, or advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

Poster 367: Analysis of patients referred to an academic gynecologic oncology clinic with an OVA1 test

Poster 368: Risk of breast cancer following ovarian cancer and the impact on overall survival

Poster 369: Outcomes of pelvic exenteration: does surgeon experience matter?

Poster 370: Trends in the use of robotic surgery for the treatment of cervical cancer

Poster 371: An economic analysis of bevacizumab in treatment of cervical cancer

Poster 372: Evaluation of a universal surgical risk calculator for quality improvement on a gynecologic oncology service

Poster 373: Is pharmacologic prophylaxis indicated for prevention of thromboembolic disease after robotic and laparoscopic hysterectomy in a gynecologic oncology practice? Analysis of morbidity and cost in 1,335 cases

Poster 374: Cross-sectional study on the impact of a natural disaster on delivery of gynecologic oncology care

Poster 375: Significant delay in the treatment of endometrial cancer based on race and insurance status

Poster 376: Patterns of care of women with low-grade cervical cytologic abnormalities

CANCER IN VULNERABLE POPULATIONS: OBESITY, ELDERLY AND THE UNDERSERVED

Poster 377: Utilizing peer teen advocates and social media to increase human papillomavirus (HPV) vaccination awareness in urban settings

Poster 378: Type I uterine cancer in United States (US)-born vs immigrants: a study of 4,834 patients

Poster 379: The use of a geographic information system to identify advanced cervical cancer patients in California

Poster 380: Sarcopenia: preoperative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer
Poster 381: Human papillomavirus (HPV) genotype prevalence in invasive vaginal cancers from a registry-based United States population

Poster 382: Body mass index and lymph node metastases in endometrial cancer: can we omit lymphadenectomy in the morbidly obese?

Poster 383: Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer

Poster 384: The increase in type I uterine cancer in 9,217 Hispanic women: a 20-year study

Poster 385: Diabetes mellitus and ovarian cancer: more complex than increasing risk

Poster 386: Borderline ovarian tumor in the elderly: impact on recurrence and survival

Poster 387: Management and outcomes for elderly women with vulvar cancer over time

Poster 388: CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity

Poster 389: Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis

Poster 390: (withdrawn at author’s request)

Poster 391: Transversus abdominis plane block in patients undergoing robotic surgery for gynecologic cancers: A randomized controlled trial

Poster 392: Impact of race, socioeconomic status, and the healthcare system on the treatment of advanced-stage ovarian cancer in California

Poster 393: Risk of complications after robotic hysterectomy for endometrial cancer in obese patients with preoperative comorbidities

Poster 394: Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women

Poster 395: The impact of obesity on 30-day morbidity and mortality after surgery for endometrial cancer

Poster 396: Levonorgestrel intrauterine device (IUD) treatment of complex atypical hyperplasia and grade 1 endometrioid endometrial cancer in postmenopausal women

Poster 397: Obesity and oncologic gynecologic surgery

Poster 398: Perceptions of obesity and cancer risk in female bariatric surgery candidates: highlighting the need for physician action for unsuspectingly obese and high-risk patients

Poster 399: Metformin use is associated with improved survival in women with endometrial cancer

Poster 400: Association between women’s breast cancer incidence and smoking rates in Japan by graphical cohort analysis

Poster 401: Insulin receptor isoform expression in ovarian cancer in African American women

Poster 402: Bariatric surgery of a means to decrease mortality in women with type I endometrial cancer: an intriguing option in a population at risk for dying of complications of metabolic syndrome

Poster 403: A population-based comparison of human papillomavirus (HPV) distribution and cervical lesions in China
Poster 404: Prospective wound protocol to decrease the incidence of wound complications in obese gynecologic oncology patients

Poster 405: Durable responses to sequential Megace in recurrent endometrial cancer

Poster 406: Quantifying obesity-related increases in cost for the surgical management of uterine cancer

Poster 407: Barriers to cervical cancer screening in victims of intimate partner violence: a Gynecologic Oncology Fellows Research Network study

Poster 408: A prospective, randomized trial on the impact of patient navigation in women with abnormal cervical cytology

Poster 409: Black race independently predicts worse survival in uterine carcinosarcoma

Poster 410: Management of advanced epithelial ovarian cancer in the elderly

Poster 411: Biguanides inhibit proliferation and decrease estrogen receptor expression in ovarian granulosa cell tumors

Poster 412: A centrosome clustering suspect, HSET, is a potential biomarker for breast cancer aggressiveness in triple-negative breast cancer (TNBC) patients

Poster 413: Comparative surgical outcomes in endometrial cancer patients staged with robotics or laparotomy 65 years and older

Poster 414: Understanding barriers and facilitators to healthy lifestyle change in African American endometrial cancer survivors and their social network

Poster 415: Body mass index (BMI) associations, including mismatch repair protein expression, in 1,051 endometrial carcinomas

Poster 416: Increasing minority participation in gynecologic oncology clinical trials through patient navigation

Poster 417: Weight-based chemotherapy dosing does not increase chemotherapy-related toxicity in obese gynecologic cancer patients

Poster 418: Minority participation in Gynecologic Oncology Group (GOG) studies

Poster 419: Positive margins on cervical excision in a high-risk population: are our best practices good enough?

Poster 420: Geographic disparities in cancer care: is optimizing the distribution of the gynecologic oncology workforce the answer? A Gynecologic Oncology Fellows Research Network study

Poster 421: Elderly patients and customized narcotic dosing after gynecologic cancer surgery

Poster 422: Contribution of human papillomavirus (HPV) genotypes to persistently abnormal cervical cytology in a high-risk Latino population

Poster 423: The characterization of morbidly obese ovarian cancer patients in the United States: a study of demographic and socioeconomic status

Poster 424: Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer
Poster 425: Weight loss in preparation for robotic-assisted surgery in the management of low-grade stage I uterine carcinoma: clinical outcomes

Poster 426: The effect of age on completion of prescribed chemoradiation among patients with cervix cancer

Poster 427: Redefining the role of obesity, race and diabetes in Type I and Type II endometrial cancers: potential targets for treatment beyond cancer itself

Poster 428: The influence of obesity upon the survival of cervical cancer patients undergoing nonsurgical therapy

Poster 429: Cervical cancer screening history in elderly patients in a rural population

Poster 430: The use of metformin in obese women with endometrial cancer may reduce the risk of cancer recurrence: a retrospective review

Poster 431: Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC)

Poster 432: Impact of obesity on the survival of cervical cancer patients

Poster 433: Definitive therapy for clinical stage I endometrial cancer in the elderly: a National Cancer Data Base study

Poster 434: Obesity and operating room efficiency by phase of robotic surgery: results from a prospective trial in gynecologic oncology

Poster 435: Adherence to follow-up after treatment for high-grade dysplasia in underserved women

Poster 436: Role of chemosensitization in elderly vaginal cancer patients: a National Cancer Data Base (NCDB) study

Poster 437: The impact of obesity on pathologic features and survival with endometrial cancer: a Gynecologic Oncology Group (GOG) LAP2 ancillary data study

Poster 438: Endometrial cancer complications and survival in morbidly obese African American and white women.

CLINICAL TRIALS
Poster 439: Predicting everolimus/letrozole treatment efficacy in patients with advanced or recurrent endometrial cancer: a biomarker study

Poster 440: Evaluation of slide storage and detection of molecular markers by immunohistochemistry (IHC) in formalin-fixed, paraffin embedded endometrial cancer tissues from a clinical trial: a GOG study

Poster 441: A phase 0 study of dasatinib in endometrial cancer

Poster 442: Hyperthermic intraperitoneal chemotherapy (HIPEC) in gynecologic malignancies

Poster 443: Salvage therapy of intensively pretreated patients with epithelial ovarian cancer and other Müllerian tract carcinomas with treosulfan and gemcitabine

Poster 444: Prospective phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel/carboplatin chemotherapy in women with uterine papillary serous carcinoma (UPSC)
**Poster 445**: T cells prepared for adoptive transfer therapy have enhanced homing ability to ovarian cancer microenvironment

**Poster 446**: Trial in progress: a randomized double-blind phase 3 trial comparing vintafolide + pegylated liposomal doxorubicin (pld) versus pld + placebo in patients with platinum-resistant ovarian cancer (proceed)

**Poster 447**: Economic impact among family caregivers of advanced ovarian cancer patients

**Poster 448**: CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: the PRECEDENT trial

**Poster 449**: Adverse event profile by folate receptor status for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

**Poster 450**: Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target

**Poster 451**: Adoptive transfer of CD3/CD28 co-stimulated T cells improves clinical outcome in patient with recurrent ovarian cancer

**Poster 452**: Para-aortic lymph node (PAN) assessment and its surgical indication in patients with stage IB-IIA cervical cancer

**Poster 453**: Laparoscopic treatment of early-stage ovarian cancer: surgical technique and outcome

**GLOBAL EFFORTS TO END WOMEN’S CANCERS**

**Poster 454**: Trends in the pathological diagnosis of serous Fallopian tube, peritoneal, and ovarian cancer in the US

**Poster 455**: Polyphyllin D, a Chinese herb, potentiates cisplatin-induced death in ovarian cancer cell lines

**Poster 456**: Epidemiologic characteristics of cervical cancer in Korean women

**Poster 457**: The malignant potential of endometrial polyps can be determined by incorporating the Endometrial Intraepithelial Neoplasia (EIN) classification

**Poster 458**: Conjugation to SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer

**Poster 459**: Quantitative assessment of immunofluorescence-based biomarkers in ovarian cancer with respect to clinical outcome

**Poster 460**: Antisense oligonucleotide suppression of human IGF-1R inhibits the growth and survival of epithelial ovarian cancer cells

**Poster 461**: The distribution of high-risk human papillomavirus genotype in high-grade cervical intraepithelial neoplasia of Korean women

**Poster 462**: Comparative study results of conventional cytology, cervical colposcopy and histopathology obtained by LEEP

**Poster 463**: Secondary primary cancer after cervical cancer

**Poster 464**: STAT1 pathway promotes progression of serous papillary endometrial cancer
Poster 465: Residual diseases after conization of women with stage IA-IB1 cervical carcinoma in region with high incidence

Poster 466: A metabolomic approach to identifying platinum resistance in ovarian cancer

Poster 467: The inhibitory effects of metformin on ovarian cancer growth mimic those seen with caloric restriction

Poster 468: Effect of dietary modulation on ovarian cancer progression and metastasis

Poster 469: Metformin use is associated with earlier stage at diagnosis in ovarian cancer patients

Poster 470: Ovarian high grade serous cancer xenografts as pre-clinical models of response to chemotherapy

Poster 471: Physician practice intentions: cervical cancer screening among HPV-vaccinated women

Poster 472: Treatment of low-risk GTN with biweekly actinomycin-D

Poster 473: (withdrawn at author’s request)

Poster 474: Cervical intraepithelial neoplasia 3+ (CIN3+) is not the right endpoint for evaluating screening algorithms, as it does not reflect cancer risk accurately

Poster 475: Triage of HPV positive women with low grade aquamous epithelial lesion (LSIL) cytology by p16/Ki-67

Poster 476: Development of serum multimarker assay for the differentiation diagnosis of ovarian cancer in patients with ovarian tumor

Poster 477: Analysis and comparison of somatic mutations between primary and recurrent ovarian carcinomas: a study in serial samples

Poster 478: Primary care providers’ knowledge of Hereditary Breast and Ovarian Cancer (HBOC) syndrome

Poster 479: Preclinical assessment of donor PBMCs in a humanized mouse model of ovarian cancer

Poster 480: Forgotten appointments = missed opportunities: Exploring the reasons for low HPV vaccine series completion rates

Poster 481: Can the need for adjuvant radiotherapy be predicted preoperatively in patients with early-stage cervical cancer?

Poster 482: In vitro and in vivo evaluation of Active Hexose Correlated Compound (AHCC) for the eradication of HPV

Poster 483: The clinical relevance of a chemo response assay for treatment of epithelial ovarian cancer

Poster 484: Disparity of cervical cancer care delivery in low-middle income countries

Poster 485: Type I interferons modulate methotrexate resistance in gestational trophoblastic neoplasia

Poster 486: Comparative costs of first-line chemotherapy for gestational trophoblastic neoplasia: a second look

Poster 487: Risk factors for recurrent high grade vaginal intraepithelial neoplasia and progression to carcinoma
**Poster 488:** Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: results from a population-based analysis

**Poster 489:** Frequency of missing data from vulvar carcinoma pathology reports: results from a population-based cohort

**Poster 490:** The impact of concurrent chemoradiation on survival compared to adjuvant radiation therapy alone in patients with node-positive vulvar cancer

**SURGICAL TECHNIQUES/ROBOTICS/MINIMALLY INVASIVE SURGERY**

**Poster 491:** Outpatient laparoscopic radical hysterectomy

**Poster 492:** A randomized controlled trial of a proficiency-based, virtual-reality robotic simulation curriculum to teach robotic suturing

**Poster 493:** Does removal of a positive sentinel node without lymphadenectomy impact pelvic sidewall control in endometrial cancer?

**Poster 494:** (withdrawn at author’s request)

**Poster 495:** Extraperitoneal paraaortic lymphadenectomy by robot-assisted laparoscopy in gynecologic oncology: the learning curve

**Poster 496:** Ultrasound guided subcostal transversus abdominis plane (tap) infiltration with liposomal bupivacaine for patients undergoing robotic-assisted hysterectomy: a retrospective cohort study

**Poster 497:** Postoperative pain scores and narcotic use in robotic-assisted versus laparoscopic hysterectomy for endometrial cancer

**Poster 498:** Does minimally invasive surgery compromise the oncologic outcome of women with high-risk non-endometrioid endometrial carcinomas

**Poster 499:** Hemostatic gelatin-thrombin matrix is associated with pelvic abscesses in patients undergoing surgery for gynecologic cancer

**Poster 500:** Robotic surgery 6-year analysis of annual peri-operative outcomes for patients with endometrial cancer

**Poster 501:** Incidence of port site hernias in robotic and laparoscopy-assisted procedures in gynecologic oncology

**Poster 502:** Do the skills of a gynecologic oncologist cross species?

**Poster 503:** Comparison of peri-operative outcomes and complication rates between conventional versus robotic-assisted laparoscopy in the evaluation and management of early, advanced stage and recurrent ovarian, Fallopian tube and primary peritoneal cancer

**SURVIVORSHIP AND SUPPORTIVE CARE**

**Poster 504:** Breaking bad news in gynecologic oncology: a national fellows’ assessment pilot study

**Poster 505:** Understanding patient learning styles in gynecologic oncology: a pilot study

**Poster 506:** Aggressive surgical debulking at time of primary and interval surgery at referral oncologic center: surgical and oncological outcomes

**Poster 507:** A low-carbohydrate nutritional program improves weight, insulin, and estrogenic parameters in obese patients with estrogen receptor positive endometrial cancer
**Poster 508:** Prognostic factors associated with long-term survival in ovarian cancer

**Poster 509:** Clinical analysis of 13 cases of vulvar Paget’s disease

**Poster 510:** A survey of female cancer patients awareness of and preferences for receiving sexual health interventions

**Poster 511:** The impact of outpatient versus inpatient referrals to hospice

**Poster 512:** Symptoms burden in subjects with cervical cancer and supportive care: preliminary result from a developing country

**Poster 513:** Chemotherapy is a reasonable option for adjuvant therapy in the treatment of high-intermediate risk endometrial cancer

**Poster 514:** A low-carbohydrate nutritional program improves adiposity, metabolic, and nutritional parameters in obese patients with estrogen receptor positive endometrial and breast cancer

**Poster 515:** National trends in the place of death and the impact of unscheduled admissions in patients with gynaecological cancer in England

**Poster 516:** Outpatient rapid desensitization for gynecologic oncology patients with mild to moderate hypersensitivity reactions to platinums

**Poster 517:** Surveillance testing in women following a diagnosis of early-stage endometrial cancer

**Poster 518:** Missed opportunities: patterns of medical care and hospice utilization among ovarian cancer patients

**Poster 519:** An afterthought: end-of-life care documentation among ovarian cancer patients

**Poster 520:** The effect of treatment modality and sequence on clinically significant chronic lymphedema in patients with vulvar carcinoma

**Poster 521:** Improved quality of life for early stage estrogen positive cancer survivors on a low carbohydrate, calorie restricted dietary intervention

**Poster 522:** Novel functions for lin28a/b in ovarian cancer predisposition and tumorigenicity

**Poster 523:** Serine protease matritase and CA-125 co-testing for ovarian cancer detection

**Poster 524:** Prevalence of cognitive impairment, pain, depression, and neuropathy in women with gynecologic malignancies

**Poster 525:** Correlation of survival-stratified proteomic and curated gene data reveal a three protein biomarker panel that predicts long-term survival of patients with primary epithelial ovarian cancer

**Poster 526:** Diminished survival of separated, divorced, or widowed uterine cancer patients: a potential focus for survivorship programs

**Poster 527:** Location of hospice referral and its impact on subsequent ED visits

**Poster 528:** BRCA mutation status is not associated with diminished ovarian reserve among women at high risk for ovarian cancer

**Poster 529:** Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery
Poster 530: A pilot study of depression prevalence and progression in patients receiving chemotherapy for gynecologic malignancies using a validated tool